CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials

@article{Lin2017CRISPRCas9MI,
  title={CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials},
  author={Ann Lin and Christopher J Giuliano and Nicole M Sayles and Jason M. Sheltzer},
  journal={eLife},
  year={2017},
  volume={6}
}
The Maternal Embryonic Leucine Zipper Kinase (MELK) has been reported to be a genetic dependency in several cancer types. MELK RNAi and small-molecule inhibitors of MELK block the proliferation of various cancer cell lines, and MELK knockdown has been described as particularly effective against the highly-aggressive basal/triple-negative subtype of breast cancer. Based on these preclinical results, the MELK inhibitor OTS167 is currently being tested as a novel chemotherapy agent in several… Expand
Combining CRISPR/Cas9 mutagenesis and a small-molecule inhibitor to probe the function of MELK in cancer
TLDR
It is reported that cancer cell lines harboring CRISPR/Cas9-induced null mutations in MELK exhibit wild-type growth in vitro, under environmental stress, in the presence of multiple chemotherapy agents, and in vivo. Expand
MELK is not necessary for the proliferation of basal-like breast cancer cells
TLDR
This study combined chemical and genetic perturbants, including the development of a novel selective maternal embryonic leucine zipper kinase (MELK) inhibitor HTH-01-091, CRISPR/Cas9-mediated MELK knockout, and a novel chemical-induced protein degradation strategy, RNA interference andCRISPR interference to validate M ELK as a therapeutic target in basal-like breast cancers. Expand
MELK expression correlates with tumor mitotic activity but is not required for cancer growth
TLDR
The results demonstrate the power of CRISPR/Cas9-based genetic approaches to investigate cancer drug targets, and call into question the rationale for treating patients with anti-MELK monotherapies. Expand
Enigmatic MELK: The controversy surrounding its complex role in cancer
TLDR
The evidence on both sides of this controversy on the purported requirement of MELK in cancer remains controversial, and mechanisms underlying the disparate growth effects observed with RNAi, pharmacological inhibition, and CRISPR remain unclear. Expand
A Conditional Dependency on MELK for the Proliferation of Triple-Negative Breast Cancer Cells
TLDR
This study investigated the in vitro dependency of cancer cells on MELK under a range of assay conditions and reveals how subtle, but important, technical variations can ultimately lead to divergent outcomes and conclusions. Expand
CRISPR deletion of MIEN1 in breast cancer cells
TLDR
It is shown that Clustered Regularly Interspaced Short Palindromic Repeat genome editing effectively produced specific genomic deletions in the MIEN1 gene which led to the abrogation of its expression in breast cancer cells. Expand
MELK is a novel therapeutic target in high-risk neuroblastoma
TLDR
It is identified that MELK expression is significantly correlated to poor overall survival, unfavorable prognosis, and high-risk status in neuroblastoma patients and its inhibitor OTSSP167 is a promising drug for further clinical development. Expand
New Insights into the Therapeutic Applications of CRISPR/Cas9 Genome Editing in Breast Cancer
TLDR
The present review provides new insights into the potential therapeutic applications of CRISPR/Cas9 for the advancement of breast cancer treatment and sheds light on the delivery methods—both viral and non-viral—that may be used to deliver the system and the barriers associated with each. Expand
CRISPER/CAS System, a Novel Tool of Targeted Therapy of Drug-resistant Lung Cancer
Lung cancer (LC) is the most common cause of cancer-related death worldwide. Patients with LC are usually diagnosed at advanced phases. Five-year survival rate in LC patients is approximately 16%.Expand
Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia
TLDR
MELK over-expression was observed in CLL cells, and correlated with higher WBC count, advanced stage, elevated LDH, increased β2-MG level, unmutated IGHV, positive ZAP-70, deletion of 17p13 and inferior prognosis of CLL patients, highlighting a novel molecule-based strategy for leukemic interventions. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 76 REFERENCES
Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer
TLDR
A high-throughput screening of a compound library followed by structure-activity relationship studies, and successfully obtained a highly potent MELK inhibitor OTSSP167 with IC50 of 0.41 nM, which should be a promising compound possibly to suppress the growth of tumor-initiating cells and be applied for treatment of a wide range of human cancer. Expand
A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia
TLDR
KAT2A inhibition demonstrated anti-AML activity by inducing myeloid differentiation and apoptosis, and suppressed the growth of primary human AMLs of diverse genotypes while sparing normal hemopoietic stem-progenitor cells. Expand
Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
TLDR
The results support the rationale for developing clinical strategies to inhibit MELK as a novel target in TNBC, and Kaplan–Meier survival and multivariable analyses identify increasing M ELK expression as being the strongest predictor of radioresistance and increased local recurrence in multiple independent datasets. Expand
Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia
TLDR
The potent anti-leukemia activity of OTS167, a small molecule MELK kinase inhibitor, in AML is investigated, and it is found that the compound induced cell differentiation and apoptosis as well as decreased migration of AML cells. Expand
MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells
TLDR
Analysis of clinical data and in vivo data indicate that MELK is a normally non-essential kinase, but is critical for BBC and thus represents a promising selective therapeutic target for the most aggressive subtype of breast cancer. Expand
Toward the Validation of Maternal Embryonic Leucine Zipper Kinase: Discovery, Optimization of Highly Potent and Selective Inhibitors, and Preliminary Biology Insight.
TLDR
The discovery and optimization of novel MELK inhibitors 8a and 8b are described that recapitulate the cellular effects observed by short hairpin ribonucleic acid (shRNA)-mediated M ELK knockdown in cellular models and a novel fluorine-induced hydrophobic collapse that locked the ligand in its bioactive conformation and led to a 20-fold gain in potency. Expand
OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases
TLDR
The results suggest that OtsSP167 may have additional mechanisms of action for cancer cell killing and caution the use of OTSSP167 as a MELK specific kinase inhibitor in biochemical and cellular assays. Expand
Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains
TLDR
It is shown that the magnitude of negative selection can be used to infer the functional importance of individual protein domains of interest, and a broader application of this approach may allow comprehensive identification of protein domains that sustain cancer cells and are suitable for drug targeting. Expand
Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression.
  • Seungho Choi, J. Ku
  • Biology, Medicine
  • Biochemical and biophysical research communications
  • 2011
TLDR
It is demonstrated that knockdown of MELK reduced the proliferation of cells with radiation or 5-FU treatment and caused changes in cell cycle, which could be associated with increased resistance of colorectal cancer cells against radiation and5-FU. Expand
High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities
TLDR
It is demonstrated that context-dependent fitness genes accurately recapitulate pathway-specific genetic vulnerabilities induced by known oncogenes and reveal cell-type-specific dependencies for specific receptor tyrosine kinases, even in oncogenic KRAS backgrounds. Expand
...
1
2
3
4
5
...